Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study
Breast Cancer · 2025-03 · 32 (2) · 329-336
DOI: 10.1007/s12282-024-01657-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer, online erschienen am 07.12.2024. Verfasst von Yosuke Aoyama und 15 weiteren Autor:innen. Beteiligte Einrichtung: Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
- Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. takayuki.ueno@jfcr.or.jp.
Zitieren
APA
Aoyama, Y., Ozaki, Y., Kizawa, R., Masuda, J., Kawai, S., Kurata, M., Maeda, T., Yoshida, K., Yamashita, N., Nishimura, M., Hosonaga, M., Fukada, I., Hara, F., Kobayashi, T., Takano, T., & Ueno, T. (2025). Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study. Breast Cancer, 32(2), 329-336. https://doi.org/10.1007/s12282-024-01657-4
Vancouver
Aoyama Y, Ozaki Y, Kizawa R, Masuda J, Kawai S, Kurata M, et al. Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study. Breast Cancer. 2025;32(2):329-336. doi:10.1007/s12282-024-01657-4
BibTeX
@article{Aoyama2025,
author = {Aoyama, Yosuke and Ozaki, Yukinori and Kizawa, Rika and Masuda, Jun and Kawai, Saori and Kurata, Mami and Maeda, Tetsuyo and Yoshida, Kazuyo and Yamashita, Nami and Nishimura, Meiko and Hosonaga, Mari and Fukada, Ippei and Hara, Fumikata and Kobayashi, Takayuki and Takano, Toshimi and Ueno, Takayuki},
title = {Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study},
journal = {Breast Cancer},
year = {2025},
volume = {32},
number = {2},
pages = {329--336},
doi = {10.1007/s12282-024-01657-4}
}
EUVIMED